drugset / Trial / NCT00422162

A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression

NCT00422162

Phase 4 Completed 339 enrolled Eli Lilly and Company Boehringer Ingelheim · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

An eight-week, randomized, double blind, two parallel groups, study to assess clinical response of duloxetine 60 milligrams (mg) and 120 mg per day in patients hospitalized for severe depression.

Timeline

Start
2007-02
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg Oral
Subject Duloxetine Small molecule 120 mg Oral